Valsamo Anagnostou, Co-Director of Thoracic Oncology Precision Medicine Center of Excellence and Division of Upper Aerodigestive Malignancies and Alex Grass Professor of Oncology at Johns Hopkins University School of Medicine, shared a post on LinkedIn:
“Insightful blog post by Katerina Karaindrou discussing our recent study on clinical and molecular outcomes of peri-operative nivolumab and nivolumab plus ipilimumab in patients with operable mesothelioma.
Liquid biopsies and ctDNA detection open a window of opportunity for treatment optimization for patients with mesothelioma, a challenging disease to manage.”
More posts featuring Valsamo Anagnostou.